Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.

Jessen F, Arbizu J, Boada M, Balasa M, Bennys K, Boban M, Bürger K, Chincarini A, Cagnin A, De Deyn PP, Düzel E, Engelborghs S, Ewers M, Exalto LG, van der Flier WM, Fortea J, Frederiksen KS, Frisoni GB, Frölich L, Garza-Martinez AJ, Grimmer T, Hanseeuw B, Hort J, Ivanoiu A, Kehoe PG, Kennelly SP, Kern S, Klöppel S, Krajčovičová L, Kramberger MG, McGuinness B, Mecocci P, Oberstein TJ, Ousset PJ, Paquet C, Perneczky R, Piazza F, Plantone D, Rainero I, Sacco G, Salmon E, Santana I, Scarmeas N, Schneider A, Schott JM, Solje E, Stefanova E, Stögmann E, Strauss M, Sutovsky S, Waldemar G, Winblad B

Open source

DOI: 10.1016/j.tjpad.2025.100259
Published: 2025 Sep
Container: The journal of prevention of Alzheimer's disease
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2025.100259,
  title = {Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.},
  author = {Jessen F and Arbizu J and Boada M and Balasa M and Bennys K and Boban M and Bürger K and Chincarini A and Cagnin A and De Deyn PP and Düzel E and Engelborghs S and Ewers M and Exalto LG and van der Flier WM and Fortea J and Frederiksen KS and Frisoni GB and Frölich L and Garza-Martinez AJ and Grimmer T and Hanseeuw B and Hort J and Ivanoiu A and Kehoe PG and Kennelly SP and Kern S and Klöppel S and Krajčovičová L and Kramberger MG and McGuinness B and Mecocci P and Oberstein TJ and Ousset PJ and Paquet C and Perneczky R and Piazza F and Plantone D and Rainero I and Sacco G and Salmon E and Santana I and Scarmeas N and Schneider A and Schott JM and Solje E and Stefanova E and Stögmann E and Strauss M and Sutovsky S and Waldemar G and Winblad B},
  year = {2025},
  journal = {The journal of prevention of Alzheimer's disease},
  doi = {10.1016/j.tjpad.2025.100259},
  url = {https://doi.org/10.1016/j.tjpad.2025.100259}
}

RIS

TY  - JOUR
TI  - Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.
AU  - Jessen F
AU  - Arbizu J
AU  - Boada M
AU  - Balasa M
AU  - Bennys K
AU  - Boban M
AU  - Bürger K
AU  - Chincarini A
AU  - Cagnin A
AU  - De Deyn PP
AU  - Düzel E
AU  - Engelborghs S
AU  - Ewers M
AU  - Exalto LG
AU  - van der Flier WM
AU  - Fortea J
AU  - Frederiksen KS
AU  - Frisoni GB
AU  - Frölich L
AU  - Garza-Martinez AJ
AU  - Grimmer T
AU  - Hanseeuw B
AU  - Hort J
AU  - Ivanoiu A
AU  - Kehoe PG
AU  - Kennelly SP
AU  - Kern S
AU  - Klöppel S
AU  - Krajčovičová L
AU  - Kramberger MG
AU  - McGuinness B
AU  - Mecocci P
AU  - Oberstein TJ
AU  - Ousset PJ
AU  - Paquet C
AU  - Perneczky R
AU  - Piazza F
AU  - Plantone D
AU  - Rainero I
AU  - Sacco G
AU  - Salmon E
AU  - Santana I
AU  - Scarmeas N
AU  - Schneider A
AU  - Schott JM
AU  - Solje E
AU  - Stefanova E
AU  - Stögmann E
AU  - Strauss M
AU  - Sutovsky S
AU  - Waldemar G
AU  - Winblad B
PY  - 2025
JO  - The journal of prevention of Alzheimer's disease
DO  - 10.1016/j.tjpad.2025.100259
UR  - https://doi.org/10.1016/j.tjpad.2025.100259
ER  -

APA

F, J., J, A., M, B., M, B., K, B., M, B., K, B., A, C., A, C., PP, D. D., E, D., S, E., M, E., LG, E., WM, V. D. F., J, F., KS, F., GB, F., L, F., AJ, G., T, G., B, H., J, H., A, I., PG, K., SP, K., S, K., S, K., L, K., MG, K., B, M., P, M., TJ, O., PJ, O., C, P., R, P., F, P., D, P., I, R., G, S., E, S., I, S., N, S., A, S., JM, S., E, S., E, S., E, S., M, S., S, S., G, W., & B, W. (2025). Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2025.100259

Source records

pubmed · retrieved 2026-09-25T19:10:03.251Z
europe-pmc · retrieved 2026-09-25T19:10:03.260Z
doaj · retrieved 2026-09-25T19:10:03.249Z
hal · retrieved 2026-09-25T19:10:03.296Z